Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study
- 8 April 2025
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (5) , 2535-2544
Abstract
Radiopharmaceuticals are a promising therapeutic strategy for tumors with less reduced resistance and minimal side effects. In our previous study, we radiolabeled the monoclonal antibody zolbetuximab, which targets CLDN18.2, with 125I, and the labeled compound showed favorable tumor targeting and retention. In this research article, [131I]I-zolbetuximab was prepared to investigate its therapeutic effect on gastric cancer using in vitro and in vivo studies. The zolbetuximab was radiolabeled with 131I using the Iodogen method. The uptake mechanism of [131I]I-zolbetuximab was investigated through an endocytosis experiment using MKN45-CLDN18.2 and MKN45 cells. The safety assessment of [131I]I-zolbetuximab was conducted in normal mice using hematoxylin/eosin (H&E) staining. The tumor uptake, biodistribution, and therapeutic efficacy of [131I]I-zolbetuximab were evaluated in nude mice bearing MKN45-CLDN18.2 tumors, while the hematological analysis, immunohistochemistry, Western blotting (WB), immunofluorescence, and H&E assays were used to further assess the treatment response and toxicity. [131I]I-Zolbetuximab exhibited a high labeling efficiency of (96.05 ± 0.23)%, a specific activity of 1.75 × 102 GBq/μmol, and good in vitro stability. The binding of [131I]I-zolbetuximab to the membrane surface receptors of MKN45-CLDN18.2 cells resulted in significant tumor uptake, retention, and favorable biodistribution in CLDN18.2-positive tumor-bearing nude mice. Safety assessments, including H&E staining, indicated no significant damage to normal mouse organs caused by the labeled compounds. In a therapeutic study involving MKN45-CLDN18.2 tumor-bearing nude mice, increasing drug dose led to notable enhancements in therapeutic efficacy and survival rates. H&E staining of mouse organs at the end of treatment showed no significant toxicity was observed across all dose groups throughout the treatment period. Furthermore, immunohistochemistry, immunoblotting, and immunofluorescence analyses conducted on mouse tumors at the treatment end point demonstrated a reduction in CLDN18.2 expression following treatment. Altogether, [131I]I-zolbetuximab displayed exceptional targeting capability, tumor retention property, significant therapeutic efficacy, and safety. These findings suggest its potential to serve as a targeted radiopharmaceutical for the treatment of CLDN18.2-positive gastric cancer.Keywords
Funding Information
- Shanghai Vista Pharmaceutical Technology Co., Ltd.
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences (SINAP-KJCX-202301)
This publication has 31 references indexed in Scilit:
- Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical ApplicationsMolecular Pharmaceutics, 2024
- [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft modelsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Antibodies as Vectors for Radiopharmaceutical Therapy2023
- In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobodyJournal of Cancer Research and Clinical Oncology, 2023
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Radiolabeled Antibodies for Imaging and Targeted Therapy2023
- Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumorsJournal of Pharmaceutical Analysis, 2023
- β-radiating radionuclides in cancer treatment, novel insight into promising approachPharmacological Research, 2020
- SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxinJournal of Neuro-Oncology, 2017
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978